Spectacular shrinking deficit followed by delayed Hemichorea-Hemiballismus: Redefining the stroke-TIA spectrum

Q3 Neuroscience

eNeurologicalSci Pub Date : 2025-10-06 DOI:10.1016/j.ensci.2025.100589

Moustafa A. Mansour , Mohamed Abdel-Fattah El-Salamoni , Hamdi Nabawi Mostafa

引用次数: 0

Abstract

Spectacular shrinking deficit (SSD) is an exceptionally rare cerebrovascular phenomenon defined by the rapid and near-complete resolution of severe neurological deficits following major hemispheric ischemia. We present the first documented case of SSD manifesting as hemichorea-hemiballismus syndrome—a striking and clinically distinct presentation that challenges current understanding of stroke sequelae. A 59-year-old diabetic female developed violent, involuntary left-sided movements one week after transient left hemiplegia, which resolved spontaneously. Neuroimaging revealed T1 hyperintensities in the right striatum without contrast enhancement, subtle diffusion abnormalities, and focal right MCA stenosis, while metabolic workup ruled out hyperglycemic chorea. The patient's refractory symptoms responded uniquely to tetrabenazine, further supporting an ischemic rather than metabolic etiology.

查看原文本刊更多论文

延迟性偏瘫-半偏瘫：重新定义卒中- tia频谱

壮观萎缩缺陷（SSD）是一种非常罕见的脑血管现象，由严重半球缺血后严重神经功能缺陷的快速和近乎完全的解决所定义。我们提出了第一个记录在案的SSD病例，表现为脑卒中半偏瘫综合征，这是一种引人注目的临床独特表现，挑战了目前对中风后遗症的理解。一名59岁女性糖尿病患者在短暂性左偏瘫一周后出现剧烈、不自主的左侧运动，并自行消退。神经影像学显示右侧纹状体T1高信号，无增强，弥散异常，局灶性右侧MCA狭窄，代谢检查排除高血糖性舞蹈病。患者的难治性症状对丁苯那嗪有独特的反应，进一步支持缺血性病因而不是代谢性病因。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

eNeurologicalSci Neuroscience-Neurology

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

62 days

期刊介绍： eNeurologicalSci provides a medium for the prompt publication of original articles in neurology and neuroscience from around the world. eNS places special emphasis on articles that: 1) provide guidance to clinicians around the world (Best Practices, Global Neurology); 2) report cutting-edge science related to neurology (Basic and Translational Sciences); 3) educate readers about relevant and practical clinical outcomes in neurology (Outcomes Research); and 4) summarize or editorialize the current state of the literature (Reviews, Commentaries, and Editorials). eNS accepts most types of manuscripts for consideration including original research papers, short communications, reviews, book reviews, letters to the Editor, opinions and editorials. Topics considered will be from neurology-related fields that are of interest to practicing physicians around the world. Examples include neuromuscular diseases, demyelination, atrophies, dementia, neoplasms, infections, epilepsies, disturbances of consciousness, stroke and cerebral circulation, growth and development, plasticity and intermediary metabolism. The fields covered may include neuroanatomy, neurochemistry, neuroendocrinology, neuroepidemiology, neurogenetics, neuroimmunology, neuroophthalmology, neuropathology, neuropharmacology, neurophysiology, neuropsychology, neuroradiology, neurosurgery, neurooncology, neurotoxicology, restorative neurology, and tropical neurology.